Literature DB >> 23303654

Management of localized gastric cancer.

Mariela A Blum1, Taketa Takashi, Akihiro Suzuki, Jaffer A Ajani.   

Abstract

Gastric cancer continues to be a fatal disease with majority of cases presenting in late stages. For patients with advanced disease, we can only recommend palliative therapy. For localized gastric cancer, the approaches vary in various regions of the world. In western countries, preoperative chemotherapy or adjuvant chemo-radiation is preferred; however in Asia, surgery followed by adjuvant chemotherapy is favored. The extent of the lymph node dissection also varies by region. D2 gastrectomy is difficult to implement in most western countries while it is standardized and is a routine in Asia. We recommend multidisciplinary evaluation of each patient before starting any therapy. The prognosis after resection depends of the pathologic stage. Long-term survivors are often <50% in the West and <70% in many Asian countries. Regional and systemic recurrences are common. Improved systemic treatments are needed. Detailed studies of molecular biology might uncover novel therapeutic targets and prognostic subgroups.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23303654     DOI: 10.1002/jso.23183

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

1.  Huge effect of arginine on survival in gastric cancer?

Authors:  Kristoffer Lassen; Kim Mortensen; Ewen Griffiths; Samir Johna; Magnus Nilsson
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-13       Impact factor: 4.553

2.  Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.

Authors:  A M Mongan; R Kalachand; S King; N J O'Farrell; D Power; N Ravi; C Muldoon; K O'Byrne; J V Reynolds
Journal:  Ir J Med Sci       Date:  2014-05-31       Impact factor: 1.568

3.  Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.

Authors:  Byung Woog Kang; Dakeun Lee; Ho Young Chung; Jae Ho Han; Young-Bae Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-05       Impact factor: 4.553

4.  Gastrectomy in advanced gastric cancer effectively palliates symptoms and may improve survival in select patients.

Authors:  Amy Collins; Ioannis Hatzaras; Carl Schmidt; Katherine Carruthers; W Scott Melvin; Pete Muscarella; E Christopher Ellison; Edward Martin; Mark Bloomston
Journal:  J Gastrointest Surg       Date:  2014-03       Impact factor: 3.452

5.  Characterization of lymph node metastasis and its clinical significance in the surgical treatment of gastric cancer.

Authors:  Chao-Hui Zuo; Hailong Xie; Jingshi Liu; Xiao-Xin Qiu; Jin-Guan Lin; Xiao Hua; Ang Qin
Journal:  Mol Clin Oncol       Date:  2014-06-03

6.  Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.

Authors:  Takeru Wakatsuki; Sebastian Stintzing; Wu Zhang; Dongyun Yang; Mizutomo Azuma; Yan Ning; Shinichi Yamauchi; Satoshi Matsusaka; Nico B Volz; Yu Sunakawa; Wasaburo Koizumi; Masahiko Watanabe; Afsaneh Barzi; Anthony B El Khoueiry; Manish A Shah; Heinz-Josef Lenz
Journal:  Pharmacogenet Genomics       Date:  2014-11       Impact factor: 2.089

7.  Adverse Prognostic Impact of Postoperative Complications After Gastrectomy for Patients With Stage II/III Gastric Cancer: Analysis of Prospectively Collected Real-World Data.

Authors:  Jeong Ho Song; Sejin Lee; Seohee Choi; Minah Cho; In Gyu Kwon; Yoo Min Kim; Taeil Son; Hyoung-Il Kim; Minkyu Jung; Woo Jin Hyung
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

8.  Reduced NKX2.1 expression predicts poor prognosis of gastric carcinoma.

Authors:  Bai-Wei Zhao; Shan-Shan Jiang; Yong-Ming Chen; Chun-Yu Huang; Yuan-Fang Li
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

9.  The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer.

Authors:  Zhiyi Zhou; Zhouyi Zhou; Jiaming Xie; Ying Cai; Shudong Yang; Ying Chen; HaoRong Wu
Journal:  Diagn Pathol       Date:  2015-07-28       Impact factor: 2.644

Review 10.  Extent of lymph node dissection for adenocarcinoma of the stomach.

Authors:  Simone Mocellin; Peter McCulloch; Hussain Kazi; Joaquin J Gama-Rodrigues; Yuhong Yuan; Donato Nitti
Journal:  Cochrane Database Syst Rev       Date:  2015-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.